Herbalife estimates profit above forecasts, reassures investors

Mon Feb 3, 2014 11:18am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(Reuters) - Herbalife Ltd (HLF.N: Quote) estimated fourth-quarter profit and sales above market forecasts, dealing a setback to investor William Ackman who has accused the nutrition and weight loss company of being a pyramid scheme and taken a big short position on the stock.

Herbalife shares rose as much as 6 percent in early trading on Monday after the company also said it had increased its share repurchase program by $500 million to $1.5 billion.

" ... Ultimately it's strong recruiting momentum around the world ... (that) is really driving the core results," said Wedbush Securities analyst Rommel Dionisio, adding that the results showed the strength of Herbalife's business model.

Monday's upbeat announcement is bad news for Ackman, who said last week that he was sticking by his $1 billion bet against the company.

Ackman has said that he expects the stock price to drop to zero. But while the shares fell 18 percent this year up to Friday's close, they have gained more than 80 percent in the past 12 months.

The activist investor said in November that his hedge fund, Pershing Square Capital Management, had lost between $400 million and $500 million on its bet against Herbalife.

Big-name investors including Carl Icahn and George Soros, who have lined up against Ackman, have done better. Icahn is up about $500 million since he first reported a stake in Herbalife last February, according to Reuters calculations.

Icahn controlled about 16.8 percent of Herbalife as of September 30, making him the company's biggest shareholder.

Ackman is relying on regulators to help his crusade against Herbalife, and he got a boost last month when U.S. Senator Edward Markey called on the Securities and Exchange Commission and the Federal Trade Commision to investigate the company.   Continued...

An Herbalife logo is shown on a poster at a clinic in the Mission District in San Francisco, California April 29, 2013. REUTERS/Robert Galbraith